TY - JOUR
T1 - Purification and characterization of epidermal growth factor (β-urogastrone) and epidermal growth factor fragments from large volumes of human urine
AU - Mount, Charles D.
AU - Lukas, Thomas J.
AU - Orth, David N.
N1 - Funding Information:
‘This work was supported in part by Research Grants 5-ROl-A.Ml9’739 and 5-ROl-GM30861 from the National Institutes of Health, USPHS, and by Research and Development Contract 09OOC with Istituto Farmacologico Serono, S.p.A., Rome, Italy.
PY - 1985/7
Y1 - 1985/7
N2 - We purified human epidermal growth factor (hEGF) and hEGF fragments from a benzoic acid precipitate of the materials not adsorbed to silica gel in 330 liters of human urine by a relatively brief, simple, and efficient method employing sequential batch absorption to and stepwise elution from CM-cellulose and DEAE-cellulose, Bio-Gel P-10 chromatography in 50 mm HCl, and three reverse-phase HPLC steps for final resolution and purification of hEGF components. Recovery of hEGF was 29%. Eight apparently homogeneous hEGF components were recovered, each of which had similar activities in a homologous hEGF radioimmunoassay and an EGF radioreceptor assay using human placental membranes. Amino acid composition analysis indicated that there were four pairs of components that represented intact 53-amino acid hEGF, hEGF-(1-52), hEGF-(1-51), and hEGF-(1-50); intact hEGF accounted for one-third of the total materials recovered. Automated Edman degradation of each component for at least 10 cycles revealed a single amino acid sequence identical to that proposed for human β-urogastrone. Similar immunoreactive hEGF components were observed in similar proportions in freshly voided urine, indicating that they were not artifacts of the purification process. Thus, multiple forms of fully biologically active hEGF (i.e., β-urogastrone) can be relatively easily and efficiently purified from large volumes of human urine.
AB - We purified human epidermal growth factor (hEGF) and hEGF fragments from a benzoic acid precipitate of the materials not adsorbed to silica gel in 330 liters of human urine by a relatively brief, simple, and efficient method employing sequential batch absorption to and stepwise elution from CM-cellulose and DEAE-cellulose, Bio-Gel P-10 chromatography in 50 mm HCl, and three reverse-phase HPLC steps for final resolution and purification of hEGF components. Recovery of hEGF was 29%. Eight apparently homogeneous hEGF components were recovered, each of which had similar activities in a homologous hEGF radioimmunoassay and an EGF radioreceptor assay using human placental membranes. Amino acid composition analysis indicated that there were four pairs of components that represented intact 53-amino acid hEGF, hEGF-(1-52), hEGF-(1-51), and hEGF-(1-50); intact hEGF accounted for one-third of the total materials recovered. Automated Edman degradation of each component for at least 10 cycles revealed a single amino acid sequence identical to that proposed for human β-urogastrone. Similar immunoreactive hEGF components were observed in similar proportions in freshly voided urine, indicating that they were not artifacts of the purification process. Thus, multiple forms of fully biologically active hEGF (i.e., β-urogastrone) can be relatively easily and efficiently purified from large volumes of human urine.
UR - http://www.scopus.com/inward/record.url?scp=0022253784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022253784&partnerID=8YFLogxK
U2 - 10.1016/0003-9861(85)90005-0
DO - 10.1016/0003-9861(85)90005-0
M3 - Article
C2 - 3874599
AN - SCOPUS:0022253784
SN - 0003-9861
VL - 240
SP - 33
EP - 42
JO - Archives of biochemistry and biophysics
JF - Archives of biochemistry and biophysics
IS - 1
ER -